Demographic reporting of the study group in recent RA studies
| Agent [reference] | Study group | Racial composition | SES* | Education |
|---|---|---|---|---|
| SES, socioeconomic status; SSZ, sulfasalazine; MTX, methotrexate; HCQ, hydroxychloroquine; CSA, ciclosporin. | ||||
| Rituximab1 | 22 | Not reported | Not reported | Not reported |
| CTLA-4Ig2 | 214 | White 194 (91%) | Not reported | Not reported |
| Black 9 (4%) | ||||
| Other 11 (5%) | ||||
| Etanercept3 | 628 | White 576 (92%) | Not reported | Not reported |
| Black 18 (3%) | ||||
| Hispanic 15 (2%) | ||||
| Asian 12 (2%) | ||||
| Other 7 (1%) | ||||
| SSZ+HCQ+MTX4 | 102 | Not reported | Not reported | Not reported |
| Leflunomide+MTX5 | 263 | White 234 (89%) | Not reported | Not reported |
| Black 15 (6%) | ||||
| Asian 8 (3%) | ||||
| Other 6 (2%) | ||||
| CSA+MTX6 | 148 | White 137 (93%) | Not reported | Not reported |
| Asian 11 (7%) | ||||
| SSZ+MTX+prednisone7 | 155 | Not reported | Not reported | Not reported |
| SSZ+HCQ+MTX8 | 195 | Not reported | Not reported | Not reported |
| Prednisone9 | 128 | Not reported | Not reported | Not reported |
| MTX10 | 123 | Not reported | Not reported | Not reported |
| Leflunomide11 | 482 | Not reported | Not reported | Not reported |
| Leflunomide12 | 358 | Not reported | Not reported | Not reported |
| MTX+leflunomide13 | 999 | Not reported | Not reported | Not reported |
| Infliximab14 | 428 | White 389 (91%) | Not reported | Not reported |
| Etanercept+MTX15 | 89 | White 70 (79%) | Not reported | Not reported |
| Etanercept16 | 633 | White 544 (86%) | Not reported | Not reported |
| Adalimumab17 | 271 | Not reported | Not reported | Not reported |